CAS: 59184-90-6; Ethyl 2-(Piperidin-4-yl)Acetate

相似化合物

169458-04-2 135716-09-5 80221-26-7

上下游产品

CAS号40110-55-2 (1-苄基-哌啶-4-亚丙基)-乙酸乙酯 | CAS号54401-85-3 4-吡啶乙酸乙酯 | CAS号135716-09-5 1-B°C-4-哌啶乙酸乙酯 | CAS号82244-11-9 4-(2-乙氧基-2-氧代亚乙... | CAS号3612-20-2 N-苄基-4-哌啶酮 | CAS号102879-50-5 4-吡啶基乙酸乙酯盐酸盐 | CAS号5382-16-1 4-羟基哌啶 | CAS号95798-23-5 4-羟基-1-哌啶甲酸苄酯 | CAS号19099-93-5 1-Cbz-4-哌啶酮 | CAS号867-13-0 磷酰基乙酸三乙酯 | CAS号51052-78-9 4-哌啶乙酸 | CAS号279236-51-0 2-(1-胺酰哌啶-4-基)乙酸乙酯 | CAS号76876-70-5 N-苄基-4-(2-羟乙基)哌啶 | CAS号135716-09-5 1-B°C-4-哌啶乙酸乙酯 | CAS号130927-83-2 1-苄基-4-哌啶乙酸 | CAS号161949-04-8 2,2'-((4-(2-(2-... | CAS号157688-46-5 1-叔丁氧羰基-4-哌啶乙酸 | CAS号120014-32-6 2-(1-benzylpipe... | CAS号71879-59-9 (1-苄基哌啶-4-基)乙酸乙酯 | CAS号98430-74-1 2-piperidin-4-y...

4-羟基-1-哌啶甲酸苄酯置于palladium On Activated Charcoal,乙二胺 氢气,Silica Gel,Pyridinium Chlorochromate体系中,用 四氢呋喃,甲醇,二氯甲烷 作为反应溶剂,20.0 °C,101.33 Kpa 条件下,反应 47.75H,反应生成 4-哌啶乙酸乙酯
参考文献:Pd/c(En)-Catalyzed Chemoselective Hydrogenation With Retention Of The N-Cbz Protective Group And Its Scope And Limitations
标题:Pd/c(En)-Catalyzed Chemoselective Hydrogenation With Retention Of The N-Cbz Protective Group And Its Scope And Limitations
摘要:A Chemoselective Method For The Hydrogenation Of Acetylene,Olefin,Azide,Nitro And Benzyl Ester Functionalities With Retention Of The Aliphatic N-Cbz Group Was Established. The Chemoselectivity Was Accomplished By Using A Combination Of 5% Pd/c-Ethylenediamine [5% Pd/c(En)] And Thf (Or 1,4-Dioxane) As A Solvent,And The Scope And Limitations Of This Methodology Were Investigated. These Results Reinforce The Utility Of N-Cbz Protective Groups In Synthetic Chemistry,Especially In Peptide Synthesis (C) 2000 Elsevier Science Ltd. All Lights Reserved.
DOI:10.1016/s0040-4020(00)00771-7

专利信息

专利号:WO-2021018023-A1
优先权日:2019-08-01
标题:Small molecule glp-1 receptor modulator
发明人：XIE FANG; YU GUANGXIA; ZHANG SHUJUAN
权利人:THE TITAN LEADING MED TECH INC
摘要:The present invention provides a new compound for modulating a Glucagon-like peptide-1 (GLP-1) receptor, and a synthesis method therefor and a pharmaceutical use thereof. This kind of compound has an obvious agonistic effect on the GLP-1 receptor, but does not have an obvious binding effect on hERG, and therefore, it is indicated that the compound has a low risk of cardiotoxicity. The compound of the present invention can be used alone as a treatment medication for type II diabetes, or be used in combination with a polypeptide GLP-1 receptor agonist such as liraglutide, or be used in combination with the treatment medication for type II diabetes of other mechanisms.

专利号:US-2014315915-A1
优先权日:2009-02-09
标题:Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs

专利号:US-9522901-B2
优先权日:2005-05-26
标题:Compositions and methods including cell death inducers and procaspase activation
发明人：HERGENROTHER PAUL J; PUTT KARSON S; PETERSON QUINN P; FAKO VALERIE
权利人:UNIV ILLINOIS
摘要:Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.

专利号:RU-2156765-C2
优先权日:1994-08-19
标 题:Derivatives of oxazolidinone carboxylic acid, method of their synthesis, pharmaceutical composition

专利号:US-2012040995-A1
优先权日:2009-02-09
标 题:Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs

专利号:US-9102661-B2
优先权日:2009-02-09
标题:Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs